MADISON, N.J., June 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new molecular test

A review of medical records of patients treated at an academic tertiary care center suggests that obese patients present to their physicians with more advanced stage and more aggressive forms of papillary thyroid cancer (PTC).

The use of single positron emission computed tomography (SPECT)/computed tomography (CT) has been reported to change clinical management in a significant number of thyroid cancer patients according to research presented in the May issue of The Journal of Nuclear Medicine.

Treatment of subclinical hypothyroidism with the medication levothyroxine appears to be related to fewer ischemic heart disease events in younger patients but this finding was not evident in older patients.

An analysis of individual data from prospective studies assessing the risks of thyroid dysfunction suggests that subclinical hyperthyroidism may be associated with increased risk of total mortality, coronary heart disease (CHD) death and incident atrial fibrillation (AF), although the risk of CHD mortality and AF is higher when thyrotropin levels are below 0.10 mIU/L.